SS
CCCC icon

SBI Securities’s C4 Therapeutics CCCC Stock Holding History

SBI Securities’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$266 Buy
101
+1
+1% +$2 ﹤0.01% 3115
2025
Q4 		$191 Sell
100
-52
-34% -$123 ﹤0.01% 3225
2025
Q3 		$337 Buy
152
+2
+1% +$5 ﹤0.01% 3136
2025
Q2 		$215 Hold
150
– – ﹤0.01% 3285
2025
Q1 		$240 Hold
150
– – ﹤0.01% 3151
2024
Q4 		$540 Buy
+150
New +$746 ﹤0.01% 2864

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SBI Securities's CCCC Position: Q1 2026 in Review

SBI Securities increased its C4 Therapeutics (CCCC) stake by 1% in Q1 2026, buying an estimated $2 and bringing the position to 101 shares worth $266. The position accounts for ﹤0.01% of the portfolio, ranked #3115.

SBI Securities first reported a position in CCCC in Q4 2024 and has held it in 6 quarters since. The position peaked at $540 in Q4 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • SBI Securities held 101 shares of C4 Therapeutics worth $266 as of Q1 2026.
  • SBI Securities bought 1 C4 Therapeutics share in Q1 2026, an estimated $2.
  • C4 Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3115 holding.
  • SBI Securities first reported a position in C4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's C4 Therapeutics position peaked at $540 in Q4 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.